| Code | CSB-RA004929MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to SAR-444559, targeting CD38, a type II transmembrane glycoprotein with dual enzymatic and receptor functions. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and functions as a regulator of intracellular calcium mobilization, playing critical roles in cell adhesion, signal transduction, and immune cell activation. This protein is highly expressed on multiple myeloma cells and various other hematological malignancies, making it an important therapeutic target. CD38 is also found on regulatory T cells, natural killer cells, and activated lymphocytes, contributing to immune regulation and inflammatory responses.
SAR-444559 represents an investigational anti-CD38 antibody developed for potential therapeutic applications in hematological disorders. This biosimilar provides researchers with a valuable tool for studying CD38-mediated signaling pathways, investigating immune cell function, evaluating antibody-dependent cellular cytotoxicity mechanisms, and exploring novel therapeutic strategies for multiple myeloma and other CD38-expressing malignancies. The antibody supports various in vitro and in vivo research models examining CD38 biology and immunotherapy approaches.
There are currently no reviews for this product.